nalmefene nasal spray · OPVEE
Small molecule
Evidence outlook
Approved: Opioid Overdose Reversal
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
Every registered study for this drug was reviewed, and none was selected as featured evidence for its approved use, so its Featured trials section is empty.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Review complete: no registered study met the criteria for featured evidence in this indication.
Its US label states: "In a pharmacokinetic study in 68 healthy adult subjects, the relative bioavailability of one 2.7 mg OPVEE nasal spray was compared to a single dose of nalmefene 1.0 mg administered as an intramuscular injection."
0 registry matches · 0 candidates
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded.
No registered studies found. Not yet ingested, or none registered.
Competitive landscape
Other Opioid receptor drugs
Naloxone (Narcan), Naltrexone (Vivitrol), Naltrexone/Acetaminophen (ALLOD-2). Compare all 4 Opioid receptor drugs
3 other tracked programmes target this mechanism, none of them ahead of this one.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Nalmefene Nasal Spray (OPVEE): this drug | Approved | Small molecule | Opioid receptor | not yet graded | No reviewed efficacy summary | |
| Naloxone (Narcan) | Approved(overall) | Small molecule | Opioid receptor | not yet graded | No reviewed efficacy summary | |
| Naltrexone (Vivitrol) | Approved(overall) | Small molecule | Opioid receptor | Partial signal | No reviewed efficacy summary | |
| Naltrexone / Acetaminophen (ALLOD-2) | Phase 2/3(overall) | — | Opioid receptor | not yet graded | No reviewed efficacy summary |
Upcoming events
No upcoming readouts on record for this asset.